|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Epithelioid glioblastoma is a recognized glioblastoma variant, recently added to the World Health Organization brain tumor classification, with similar prognosis as the classic variant and B-Raf V600E mutations in 50% of the cases.
|
31258848 |
2019 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Epithelioid GBM with BRAF V600E mutation can be considered a good treatment indication for precision medicine, and this patient-derived cell line should be useful for prediction of the tumor response and clarification of its biological characteristics.
|
31345255 |
2019 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
BRAF V600E mutation and BRAF VE1 immunoexpression profiles in different types of glioblastoma.
|
30013630 |
2018 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
Here, we describe a case of systemic metastases of a clonal subpopulation of BRAF V600E mutated glioblastoma in a patient previously treated with surgery, radiation, temozolomide and bevacizumab.
|
29744614 |
2018 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
This case suggests that the BRAF V600E mutation may be involved in the malignant transformation to glioblastoma.
|
26404554 |
2016 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
An institutional cohort of 105 brain tumors (51 dysembryoplastic neuroepithelial tumors (DNTs), 14 subependymal giant cell astrocytomas (SEGAs), 12 glioblastoma with neuronal marker expression (GBM-N), and 28 pleomorphic xanthoastrocytomas (PXAs)) from 100 patients were investigated for the presence of BRAF(V600E) by direct sequencing.
|
25346165 |
2015 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
These findings suggest that epithelioid GBM may arise from a PXA with a BRAF V600E mutation.
|
24894018 |
2014 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
BRAF V600E mutational analyses should be performed on E-GBMs, particularly in all pediatric and young-aged adults, given the potential for BRAF inhibitor therapy in this subset of GBM patients.
|
23552385 |
2013 |
|
rs121913377
|
|
|
0.090 |
GeneticVariation |
BEFREE |
BRAF V600E mutations were identified in only 2 of 71 (2.8%) glioblastoma (GBM) analyzed, including 1 of 9 (11.1%) giant cell GBM (gcGBM).
|
21479234 |
2011 |